Who are Delamanid in Oral Dosage Form's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Delamanid (DLM).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/delamanid-in-oral-dosage-form.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Delamanid in Oral Dosage Form — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Delamanid in Oral Dosage Form (Delamanid in Oral Dosage Form) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mycobacterial cell wall synthesis inhibitor. Area: Infectious Disease.

phase 3 Mycobacterial cell wall synthesis inhibitor DprE1 (decaprenylphosphoryl-arabinose-1-phosphatase) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Delamanid in Oral Dosage Form (Delamanid in Oral Dosage Form) — Wits Health Consortium (Pty) Ltd. Delamanid inhibits mycobacterial cell wall synthesis by targeting mycolic acid production, thereby killing Mycobacterium tuberculosis.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Delamanid in Oral Dosage Form TARGET	Delamanid in Oral Dosage Form	Wits Health Consortium (Pty) Ltd	phase 3	Mycobacterial cell wall synthesis inhibitor	DprE1 (decaprenylphosphoryl-arabinose-1-phosphatase)
Delamanid (DLM)	Delamanid (DLM)	Wuhan Pulmonary Hospital	phase 3	Mycobacterial cell wall synthesis inhibitor	DprE1 (decaprenylphosphoryl-β-D-ribose 2'-epimerase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mycobacterial cell wall synthesis inhibitor class)

Wits Health Consortium (Pty) Ltd · 1 drug in this class
Wuhan Pulmonary Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Delamanid in Oral Dosage Form — Competitive Intelligence Brief. https://druglandscape.com/ci/delamanid-in-oral-dosage-form. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab